$THER .0025 ^8% Acquires Exclusive Landmark All

New Post Public Reply Private Reply Replies (0) Message Board
FLA
137
$THER .0025 ^8% Acquires Exclusive Landmark


All Content and Data provided by Third-Parties — Terms of Use
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
PR NEWSWIRE 8:30 AM ET 4/3/2023
Symbol Last Price Change
THER 0.0025up +0.0002 (+8.695652%)
QUOTES AS OF 10:43:55 AM ET 04/03/2023
Company's patent portfolio expands to 10

GOLDEN, Colo. , April 3, 2023 /PRNewswire/ -- Theralink Technologies, Inc.(THER) (OTC: THER) ("Theralink(THER)" or the "Company" , a precision oncology company with a novel phosphoprotein and protein assay for breast cancer, today announced that it has acquired an exclusive license from Vanderbilt University for a U.S. patent related to methods for predicting patient response to immunotherapies in cancers, US 10,969,392, expanding the Company's patent portfolio to 10.

Theralink (THER) has licensed the patent from Vanderbilt University, strengthening and extending Theralink's(THER) current IP portfolio that covers specific "predictive" biomarkers. Predictive biomarkers are used to identify patients with cancers that require specific, personalized therapeutics. In essence, they define what are called "companion diagnostics" wherein the biomarker is used to identify classes of patients that will best respond to a specific drug. Theralink's(THER) existing licensed patents cover specific predictive biomarkers that cover a range of therapeutic classes.

Emanuel Petricoin , Ph.D., Chair of Theralink's(THER)Science Advisory Board, stated, "Immuno-oncology is one of the most exciting areas in the treatment of cancer today. However, despite the great success and promise of immunotherapies, many patients do not respond to this class of drugs, and there are significant toxicities associated with them. This important patent from discoveries made in the Balko laboratory at Vanderbilt University Medical Center is a significant addition to Theralink's(THER) biomarker collection, greatly enhancing our existing CLIA Theralink Assay portfolio."

Dr. Justin Balko, PharmD. Ph.D., Associate Professor of Medicine at Vanderbilt, commented, "We are pleased to advance this important biomarker into the clinic with the ultimate goal of aiding precision medicine in the use of immunotherapy in breast cancer and other tumor types. Migrating this biomarker to a clinically-accessible platform in tandem with ongoing phase III validation efforts will certainly accelerate its impact."

Dr. Mick Ruxin, CEO of Theralink(THER), added, "This patent has very broad and important claims that will immediately synergize with the commercially available Theralink Assay offered today. I am excited about the potential clinical impact that the new licensed protein biomarkers, such as MHCII, will have at the bedside. This is one of the first of the so-called 'pan-tumor' predictive markers that Theralink(THER) will be utilizing: working not just for patients with breast cancer but for most solid tumor cancers."

New Patent Details:
Issued patent 10,969,392: Methods and systems for predicting response to immunotherapies for treatment of cancer, relates to the use of specific predictive biomarkers that can be used to identify which cancer patients will respond to the powerful and exciting new class of therapeutics called immunotherapies. The patent covers the use of the protein markers MHC-II, along with 16 other important protein markers found expressed in tumor cells and surrounding immune cells wherein immunotherapy treatments can be personalized and tailored for any cancer patient based on the protein expression pattern of these markers.

About Theralink Technologies, Inc.(THER)
Theralink Technologies (THER) is a proteomics-based, precision medicine company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's(THER) technology targets multiple areas of oncology and drug development. In addition to the Company's first assay for advanced breast cancer, Theralink(THER) is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink(THER) provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink(THER) intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies(THER) with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.

Cision View original content:https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

SOURCE Theralink Technologies(THER)
I ONLY POST WHAT I PLAY
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 118

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 180

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 144

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 17

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 71

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 84

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 88

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading

Top 5 Most Recently Viewed Articles

Nabors Industries Expands Reach with Parker Wellbore Buyout

Updated Category News Views 205

Nabors Industries Completes Acquisition of Parker Wellbore Nabors Industries Ltd. (NYSE: NBR) has officially concluded its acquisition of Parker Wellbore, a strategic move that strengthens Nabors' leadership in drilling and associated value-added services. This acquisition not only cements Nabors' robust market position but also enhances its service capabilities across...

Continue Reading
Utz, Integer, Arcosa, Dominion: Fair Deals for Shareholders?

Updated Category News Views 18

Investor Concerns Over Recent M&A Deals Today, you can't shake a stick without hitting some M&A news and, frankly, these deals with Utz, Integer, Arcosa, and Dominion have got investors squirming in their seats. With insiders possibly raking in the dough, shareholders are left wondering if they’re just getting table scraps. And you know what makes folks justifiably...

Continue Reading
Revolutionizing Business Growth with QuickBooks AI Tools

Updated Category News Views 151

Revolutionizing Business Growth with QuickBooks AI Tools Software Experts recently spotlighted QuickBooks for its innovative approach in transforming business financial forecasting and planning. The introduction of AI-driven agents in QuickBooks signifies a major transition towards more connected and automated financial management, streamlining processes while enhancing...

Continue Reading
CMB Certification: A New Era for Sustainable Wellness Brands

Updated Category News Views 234

CMB Certification: Pioneering a Path for Wellness Brands Crunchy Mama Box (CMB) has recently unveiled its CMB Certification Program, an initiative that aims to validate wellness brands dedicated to sustainability, ethical practices, and social contributions. This certification serves as a valuable tool for consumers, empowering them to make well-informed decisions while...

Continue Reading
Prevounce Health Integrates AI for Enhanced Patient Care Solutions

Updated Category News Views 303

Prevounce Health Enhances Remote Care with Innovative AI Insights Prevounce Health has recently unveiled an exciting feature that integrates artificial intelligence into its remote care management offerings. This initiative aims to provide AI-generated summaries and personalized recommendations for patients enrolled in remote care management programs, transforming the...

Continue Reading